---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-000675"
form_type: "8-K"
ticker: "WINT"
cik: "0000946486"
company_name: "WINDTREE THERAPEUTICS INC /DE/"
filed_at: "2025-01-08T23:59:59+00:00"
generated_at: "2026-05-28T07:32:13.213228+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "medium"
source: SEC EDGAR
---

# Windtree shifts strategy to acquire FDA-approved product companies via all-stock deals

## Summary
- New corporate strategy targets acquisition of small companies with FDA-approved products using equity.
- Management aims to leverage commercialization expertise across large pharma and biotech to optimize acquired assets.
- Company will continue advancing its cardiovascular and oncology pipeline alongside revenue-generating acquisitions.
- CEO Jed Latkin says strategy marks a new chapter focused on near-term revenue and shareholder value.

## SEC filing metadata
- accession: 0001437749-25-000675
- form_type: 8-K
- ticker: WINT
- cik: 0000946486
- company_name: WINDTREE THERAPEUTICS INC /DE/
- filed_at: 2025-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: medium
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/946486/000143774925000675/0001437749-25-000675-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/946486/000143774925000675/wint20250107_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-000675
- JSON: https://secwatch.observer/filing/0001437749-25-000675.json
- Plain text: https://secwatch.observer/filing/0001437749-25-000675.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.